News
03-01-2011, 10:30 PM
Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.
More... (http://www.news-medical.net/news/20110302/NCI-sponsors-multi-center-phase-2-study-of-entinostat-anastrozole-combination-in-triple-negative-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20110302/NCI-sponsors-multi-center-phase-2-study-of-entinostat-anastrozole-combination-in-triple-negative-breast-cancer.aspx)